Horizon Investments LLC Reduces Stock Holdings in Abbott Laboratories $ABT

Horizon Investments LLC reduced its position in shares of Abbott Laboratories (NYSE:ABT) by 45.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 59,169 shares of the healthcare product maker’s stock after selling 48,862 shares during the quarter. Horizon Investments LLC’s holdings in Abbott Laboratories were worth $7,376,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in ABT. Harbor Capital Advisors Inc. bought a new stake in Abbott Laboratories during the fourth quarter valued at approximately $27,000. Cloud Capital Management LLC bought a new position in Abbott Laboratories in the third quarter worth approximately $29,000. Guerra Advisors Inc bought a new position in Abbott Laboratories in the third quarter worth approximately $31,000. Bridge Generations Wealth Management LLC purchased a new position in shares of Abbott Laboratories during the 3rd quarter worth $33,000. Finally, Copia Wealth Management bought a new stake in shares of Abbott Laboratories during the 3rd quarter valued at $38,000. Institutional investors own 75.18% of the company’s stock.

Insiders Place Their Bets

In related news, Director Daniel J. Starks bought 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The stock was purchased at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the completion of the transaction, the director owned 6,738,817 shares in the company, valued at $732,711,572.41. The trade was a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Mary K. Moreland sold 613 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the transaction, the executive vice president directly owned 104,291 shares of the company’s stock, valued at $12,053,953.78. The trade was a 0.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders purchased 22,200 shares of company stock worth $2,215,100 and sold 3,055 shares worth $353,097. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Trading Down 1.4%

Shares of Abbott Laboratories stock opened at $89.51 on Friday. Abbott Laboratories has a fifty-two week low of $89.14 and a fifty-two week high of $139.06. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.18 and a current ratio of 1.39. The company has a market capitalization of $155.90 billion, a P/E ratio of 25.07, a P/E/G ratio of 1.49 and a beta of 0.66. The company has a fifty day moving average of $104.33 and a 200 day moving average of $116.09.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period last year, the firm earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.8%. Abbott Laboratories’s payout ratio is currently 70.59%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ABT shares. Wells Fargo & Company decreased their target price on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Raymond James Financial cut their price target on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Royal Bank Of Canada decreased their price objective on Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Daiwa Securities Group cut Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective on the stock. in a research report on Wednesday, April 22nd. Finally, Leerink Partners cut their price objective on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $119.43.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.